Clinical trials: Streptococcus Pneumoniae Vaccines
Streptococcus Pneumoniae
Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months
Streptococcus pneumoniae is a major cause of serious bacterial infections, particularly among young children. Over 30 different types of the pneumococcus germ can cause invasive disease, but 7 types (namely serotypes 4, 6B, 9V…
- Trial name
- P13UK (NCT01425372)
- Where
- United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Prof. Elizabeth Miller
Vaccines
Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India
This is a Phase 4, open-label, single-arm, multicenter study in which subjects 6 to 17 years of age will receive 1 dose of 13vPnC.
- Trial name
- NCT03777865
- Testing
- 13vPnC
- Where
- 4 sites in India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal Infections
Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France
CAP'Hospi is an observational, multicentric study in France which primary objective is to describe the proportion of Community Acquired Pneumonia due to serotypes included in PCV20 among adults hospitalized for CAP
- Conditions
- Pneumonia, Pneumococcal Infections, Community-acquired Pneumonia
- Trial name
- CAP'Hospi (NCT05380193)
- Where
- 5 sites in France
- Volunteers
- 1,017 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
- Trial name
- NCT07300644
- Testing
- Sinovac PCV24, Prevnar®
- Where
- 3 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)
Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)
The purpose of this study in healthy toddlers who have not previously been immunized against MenC infection and who completed their primary immunization series with PCV-7 (3 vaccinations) during infancy is to demonstrate that the…
- Trial name
- NCT00617760
- Testing
- Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7), Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
- Where
- 27 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Pfizer
Streptococcus Pneumoniae, Haemophilus Influenzae
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of a non-typable Haemophilus influenzae and pneumococcal candidate vaccine in young adults.
- Trial name
- NCT00814489
- Testing
- GSK2231395A, Engerix-B
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis A
PCV13 + Hepatitis A Vaccine for Adults
The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine; Prevenar13) vaccine in adults.
- Trial name
- PCV13+HepA (NCT01926860)
- Testing
- Prevenar13, Hepatitis A vaccine
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Infections, Streptococcal, Streptococcus Pneumoniae
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S.
- Trial name
- FinIP (NCT00861380)
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- Finland
- Volunteers
- 41,188 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection, Pneumococcal Infections
Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults
S. pneumoniae is frequently isolated from nasal swabs of healthy subjects, but it can also cause severe diseases (pneumonia, bacteraemia, meningitis and sepsis).HIV-infected subjects are more sensitive to invasive diseases and…
- Trial name
- PCV13HIV2011 (NCT02123433)
- Testing
- pneumococcal conjugate 13 valent vaccine
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- University of Siena
Hepatitis A
A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
The purpose of this study is to assess the efficacy in young children in preventing acute otitis media due to vaccine serotype pneumococcal or non typable Hemophilus influenza, following immunization with an 11-valent…
- Trial name
- NCT00119743
- Testing
- undecavalent pneumococcal-protein D conjugate vaccine
- Where
- 41 sites in Czechia, Slovakia
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
PNAG-expressing Pathogenic Microbes Vaccine
A Study of AV0328 Administered to Healthy Adult Volunteers
AV0328 is a novel vaccine candidate intended to raise antibodies to the glucosamine backbone of naturally occurring Poly N-acetyl glucosamine (PNAG), a capsular polysaccharide expressed on the surface of a wide array of microbes.
- Trial name
- NCT02853617
- Testing
- AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alopexx Vaccine, LLC
Fever After Vaccination, Fever
Fever After Simultaneous Versus Sequential Vaccination in Young Children
A prospective, randomized open-label clinical trial that will be conducted during the 2017-2018 influenza season. During the 2017-2018 season, approximately 280 children will be enrolled at Duke University Medical Center and…
- Conditions
- Fever After Vaccination, Fever, Febrile Seizure
- Trial name
- NCT03165981
- Testing
- PCV13, DTaP, IIV
- Where
- 3 sites in United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Duke University
Rheumatoid Arthritis, Systemic Lupus
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited by pneumococcal vaccination using 13-valent…
- Conditions
- Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome, Systemic Vasculitis
- Trial name
- IPS-BOOSTER (NCT03762824)
- Testing
- 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Region Skane
Pneumococcal Disease
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older.
- Trial name
- NCT05569954
- Testing
- V116, PPSV23
- Where
- 55 sites in Argentina, Australia and 9 more
- Volunteers
- 1,484 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
CLL, Vaccine Response
Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia
A randomized, multi-centre trial was conducted between 2013-2016, including 128 patients with untreated CLL from eight hematological clinics in Sweden.
- Trial name
- NCT05316831
- Testing
- PCV13, PPSV23
- Where
- Sweden
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Region Örebro County
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
- Trial name
- NCT03835975
- Testing
- 13vPnC, PPSV23, 20vPnC
- Where
- 42 sites in United States, Sweden
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13.
- Trial name
- NCT05408429
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 43 sites in Hungary, Poland and 1 more
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Aging
Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines
This is a prospective, single-site, randomized, then open-label study designed to develop a detailed transcriptional and epigenetic profile of the immune response to pneumococcal vaccination with conjugated and non-conjugated…
- Trial name
- NCT03104075
- Testing
- Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Jackson Laboratory
Healthy Subjects
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
This open-label, multicenter study is designed to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy children aged more than 15 months up to less than 18 years.
- Trial name
- NCT00761631
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 36 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Pfizer
Infections, Streptococcal
Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
The purpose of this trial is to evaluate the immunogenicity and safety of a pneumococcal conjugate vaccine when co-administered with DTPa-IPV-Hib or DTPa-HBV-IPV/Hib in infants as a three-dose primary immunisation course during…
- Trial name
- NCT00652951
- Testing
- GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™), Infanrix™ hexa., Pediacel™
- Where
- Netherlands
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline